#BEGIN_DRUGCARD DB01861

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C15H24N2O17P2

# Chemical_IUPAC_Name:
[({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolized into UDPgalactose and UDPglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Glucose-Uridine-C1,5'-Diphosphate

# HET_ID:
GUD

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8-,9-,10+,11+,12-,13+,14+/m0/s1

# InChI_Key:
InChIKey=HSCJRCZFDFQWRP-LJMZODOWSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1861

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
566.3018

# Molecular_Weight_Mono:
566.055020376

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1GUQ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.4

# Predicted_LogS:
-1.6

# Predicted_Water_Solubility:
1.50e+01 g/l

# Primary_Accession_No:
DB01861

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936243

# PubChem_Substance_ID:
46507150

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01669

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@H](O[P@](O)(=O)O[P@@](O)(=O)OC[C@@H]2O[C@H]([C@H](O)[C@H]2O)N2C=CC(=O)NC2=O)[C@@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:33 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X06226

# Drug_Target_1_GenBank_ID_Protein:
41524

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
galT

# Drug_Target_1_Gene_Sequence:
>1044 bp
ATGACGCAATTTAATCCCGTTGATCATCCACATCGCCGCTACAACCCGCTCACCGGGCAA
TGGATTCTGGTTTCACCGCACCGCCTAAGCCCCTGGCAGGGGGCGCAGGAAACGCCAGCC
AAACAGGTGTTACCTGCGCACGATCCAGATTGCTTCCTCTGCGCAGGTAATGTGCGGGTG
ACAGGCGATAAAAACCCCGATTACACCGGGACTTACGTTTTCACTAATGACTTTGCGGCT
TTGATGTCTGACACGCCAGATGCGCCAGAAAGTCACGATCCGCTGATGCGTTGCCAGAGC
GCGCGCGGCACCAGCCGGGTGATCTGCTTTTCACCGGATCACAGTAAAACGCTGCCAGAG
CTCAGCGTTGCAGCATTGACGGAAATCGTCAAAACCTGGCAGGAGCAAACCGCAGAACTG
GGGAAAACGTACCCATGGGTGCAGGTTTTTGAAAACAAAGGCGCGGCGATGGGCTGCTCT
AACCCGCATCCGCACGGTCAGATTTGGGCAAATAGCTTCCTGCCTAACGAAGCTGAGCGC
GAAGACCGCCTGCAAAAAGAATATTTTGCCGAACAGAAATCACCAATGCTGGTGGATTAT
GTTCAGCGCGAGCTGGCAGACGGTAGCCGTACCGTTGTCGAAACCGAACACTGGTTAGCC
GTCGTGCCTTACTGGGCTGCCTGGCCGTTCGAAACGCTACTGCTGCCCAAAGCCCACGTT
TTACGGATCACCGATTTGACCGACGCCCAGCGCAGCGATCTGGCGCTGGCGTTGAAAAAG
CTGACCAGTCGTTATGACAACCTCTTCCAGTGCTCCTTCCCCTACTCTATGGGCTGGCAC
GGCGCGCCATTTAATGGCGAAGAGAATCAACACTGGCAGCTGCACGCGCACTTTTATCCG
CCTCTGCTGCGCTCCGCCACCGTACGTAAATTTATGGTTGGTTATGAAATGCTGGCAGAG
ACCCAGCGAGACCTGACCGCAGAACAGGCAGCAGAGCGTTTGCGCGCAGTCAGCGACATC
CATTTTCGCGAATCCGGAGTGTAA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
10820011	Geeganage S, Ling VW, Frey PA: Roles of two conserved amino acid residues in the active site of galactose-1-phosphate uridylyltransferase: an essential serine and a nonessential cysteine. Biochemistry. 2000 May 9;39(18):5397-404.
2823224	Cornwell TL, Adhya SL, Reznikoff WS, Frey PA: The nucleotide sequence of the gal T gene of Escherichia coli. Nucleic Acids Res. 1987 Oct 12;15(19):8116.
3022232	Lemaire HG, Muller-Hill B: Nucleotide sequences of the gal E gene and the gal T gene of E. coli. Nucleic Acids Res. 1986 Oct 10;14(19):7705-11.
3158881	Debouck C, Riccio A, Schumperli D, McKenney K, Jeffers J, Hughes C, Rosenberg M, Heusterspreute M, Brunel F, Davison J: Structure of the galactokinase gene of Escherichia coli, the last (?) gene of the gal operon. Nucleic Acids Res. 1985 Mar 25;13(6):1841-53.
321007	Wong LJ, Sheu KF, Lee SL, Frey PA: Galactose-1-phosphate uridylyltransferase: isolation and properties of a uridylyl-enzyme intermediate. Biochemistry. 1977 Mar 8;16(5):1010-6.
7669762	Wedekind JE, Frey PA, Rayment I: Three-dimensional structure of galactose-1-phosphate uridylyltransferase from Escherichia coli at 1.8 A resolution. Biochemistry. 1995 Sep 5;34(35):11049-61.
8794735	Wedekind JE, Frey PA, Rayment I: The structure of nucleotidylated histidine-166 of galactose-1-phosphate uridylyltransferase provides insight into phosphoryl group transfer. Biochemistry. 1996 Sep 10;35(36):11560-9.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9063869	Thoden JB, Ruzicka FJ, Frey PA, Rayment I, Holden HM: Structural analysis of the H166G site-directed mutant of galactose-1-phosphate uridylyltransferase complexed with either UDP-glucose or UDP-galactose: detailed description of the nucleotide sugar binding site. Biochemistry. 1997 Feb 11;36(6):1212-22.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2590

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
39646

# Drug_Target_1_Name:
Galactose-1-phosphate uridylyltransferase

# Drug_Target_1_Number_of_Residues:
348

# Drug_Target_1_PDB_ID:
1HXQ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01087	GalP_UDP_transf
PF02744	GalP_UDP_tr_C

# Drug_Target_1_Protein_Sequence:
>Galactose-1-phosphate uridylyltransferase
MTQFNPVDHPHRRYNPLTGQWILVSPHRAKRPWQGAQETPAKQVLPAHDPDCFLCAGNVR
VTGDKNPDYTGTYVFTNDFAALMSDTPDAPESHDPLMRCQSARGTSRVICFSPDHSKTLP
ELSVAALTEIVKTWQEQTAELGKTYPWVQVFENKGAAMGCSNPHPHGQIWANSFLPNEAE
REDRLQKEYFAEQKSPMLVDYVQRELADGSRTVVETEHWLAVVPYWAAWPFETLLLPKAH
VLRITDLTDAQRSDLALALKKLTSRYDNLFQCSFPYSMGWHGAPFNGEENQHWQLHAHFY
PPLLRSATVRKFMVGYEMLAETQRDLTAEQAAERLRAVSDIHFRESGV

# Drug_Target_1_Reaction:
UDP-glucose + alpha-D-galactose 1-phosphate = alpha-D-glucose 1-phosphate + UDP-galactose

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
UDP-glucose + alpha-D-galactose 1-phosphate = alpha-D-glucose 1-phosphate + UDP-galactose

# Drug_Target_1_SwissProt_ID:
P09148

# Drug_Target_1_SwissProt_Name:
GAL7_ECOLI

# Drug_Target_1_Synonyms:
EC 2.7.7.12
Gal-1-P uridylyltransferase
UDP-glucose--hexose-1-phosphate uridylyltransferase

# Drug_Target_1_Theoretical_pI:
6.45

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GALE

# Drug_Target_2_GenBank_ID_Gene:
L41668

# Drug_Target_2_GenBank_ID_Protein:
1119217

# Drug_Target_2_GeneCard_ID:
GALE

# Drug_Target_2_Gene_Name:
GALE

# Drug_Target_2_Gene_Sequence:
>1047 bp
ATGGCAGAGAAGGTGCTGGTAACAGGTGGGGCTGGCTACATTGGCAGCCACACGGTGCTG
GAGCTGCTGGAGGCTGGCTACTTGCCTGTGGTCATCGATAACTTCCATAATGCCTTCCGT
GGAGGGGGCTCCCTGCCTGAGAGCCTGCGGCGGGTCCAGGAGCTGACAGGCCGCTCTGTG
GAGTTTGAGGAGATGGACATTTTGGACCAGGGAGCCCTACAGCGTCTCTTCAAAAAGTAC
AGCTTTATGGCGGTCATCCACTTTGCGGGGCTCAAGGCCGTGGGCGAGTCGGTGCAGAAG
CCTCTGGATTATTACAGAGTTAACCTGACCGGGACCATCCAGCTTCTGGAGATCATGAAG
GCCCACGGGGTGAAGAACCTGGTGTTCAGCAGCTCAGCCACTGTGTACGGGAACCCCCAG
TACCTGCCCCTTGATGAGGCCCACCCCACGGGTGGTTGTACCAACCCTTACGGCAAGTCC
AAGTTCTTCATCGAGGAAATGATCCGGGACCTGTGCCAGGCAGACAAGACTTGGAACGTA
GTGCTGCTGCGCTATTTCAACCCCACAGGTGCCCATGCCTCTGGCTGCATTGGTGAGGAT
CCCCAGGGCATACCCAACAACCTCATGCCTTATGTCTCCCAGGTGGCGATCGGGCGACGG
GAGGCCCTGAATGTCTTTGGCAATGACTATGACACAGAGGATGGCACAGGTGTCCGGGAT
TACATCCATGTCGTGGATCTGGCCAAGGGCCACATTGCAGCCTTAAGGAAGCTGAAAGAA
CAGTGTGGCTGCCGGATCTACAACCTGGGCACGGGCACAGGCTATTCAGTGCTGCAGATG
GTCCAGGCTATGGAGAAGGCCTCTGGGAAGAAGATCCCGTACAAGGTGGTGGCACGGCGG
GAAGGTGATGTGGCAGCCTGTTACGCCAACCCCAGCCTGGCCCAAGAGGAGCTGGGGTGG
ACAGCAGCCTTAGGGCTGGACAGGATGTGTGAGGATCTCTGGCGCTGGCAGAAGCAGAAT
CCTTCAGGCTTTGGCACGCAAGCCTGA

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
10801319	Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM: Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose 4-epimerase. Biochemistry. 2000 May 16;39(19):5691-701.
11279193	Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM: Molecular basis for severe epimerase deficiency galactosemia. X-ray structure of the human V94m-substituted UDP-galactose 4-epimerase. J Biol Chem. 2001 Jun 8;276(23):20617-23. Epub 2001 Mar 7.
8593531	Daude N, Gallaher TK, Zeschnigk M, Starzinski-Powitz A, Petry KG, Haworth IS, Reichardt JK: Molecular cloning, characterization, and mapping of a full-length cDNA encoding human UDP-galactose 4'-epimerase. Biochem Mol Med. 1995 Oct;56(1):1-7.
9326324	Quimby BB, Alano A, Almashanu S, DeSandro AM, Cowan TM, Fridovich-Keil JL: Characterization of two mutations associated with epimerase-deficiency galactosemia, by use of a yeast expression system for human UDP-galactose-4-epimerase. Am J Hum Genet. 1997 Sep;61(3):590-8.
9538513	Maceratesi P, Daude N, Dallapiccola B, Novelli G, Allen R, Okano Y, Reichardt J: Human UDP-galactose 4' epimerase (GALE) gene and identification of five missense mutations in patients with epimerase-deficiency galactosemia. Mol Genet Metab. 1998 Jan;63(1):26-30.
9973283	Wohlers TM, Christacos NC, Harreman MT, Fridovich-Keil JL: Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia. Am J Hum Genet. 1999 Feb;64(2):462-70.

# Drug_Target_2_HGNC_ID:
HGNC:4116

# Drug_Target_2_HPRD_ID:
06092

# Drug_Target_2_ID:
2762

# Drug_Target_2_Locus:
1p36-p35

# Drug_Target_2_Molecular_Weight:
38282

# Drug_Target_2_Name:
UDP-glucose 4-epimerase

# Drug_Target_2_Number_of_Residues:
348

# Drug_Target_2_PDB_ID:
1EK6

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_2_Protein_Sequence:
>UDP-glucose 4-epimerase
MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRGGGSLPESLRRVQELTGRSV
EFEEMDILDQGALQRLFKKYSFMAVIHFAGLKAVGESVQKPLDYYRVNLTGTIQLLEIMK
AHGVKNLVFSSSATVYGNPQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNA
VLLRYFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDYDTEDGTGVRD
YIHVVDLAKGHIAALRKLKEQCGCRIYNLGTGTGYSVLQMVQAMEKASGKKIPYKVVARR
EGDVAACYANPSLAQEELGWTAALGLDRMCEDLWRWQKQNPSGFGTQA

# Drug_Target_2_Reaction:
UDP-glucose = UDP-galactose

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes two distinct but analogous reactions:the epimerization of UDP-glucose to UDP-galactose and the epimerization of UDP-N-acetylglucosamine to UDP-N- acetylgalactosamine

# Drug_Target_2_SwissProt_ID:
Q14376

# Drug_Target_2_SwissProt_Name:
GALE_HUMAN

# Drug_Target_2_Synonyms:
EC 5.1.3.2
Galactowaldenase
UDP-galactose 4-epimerase

# Drug_Target_2_Theoretical_pI:
6.71

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01861
